Real-World Data Analysis of Pembrolizumab Monotherapy for NSCLC Using Japanese Postmarketing All-Case Surveillance Data

Hideki Terai, Kenzo Soejima, Asanao Shimokawa, Hidehito Horinouchi, Junichi Shimizu, Tetsunari Hase, Ryota Kanemaru, Kana Watanabe, Kiichiro Ninomiya, Naoko Aragane, Noriko Yanagitani, Yoshihiko Sakata, Masahiro Seike, Daichi Fujimoto, Masashi Kasajima, Akihito Kubo, Sojiro Kusumoto, Yoshitaka Oyamada, Keiichi Fujiwara, Masahide Mori, Midori Hashimoto, Masato Shingyoji, Masahiro Kodani, Jin Sakamoto, Toshihiko Agatsuma, Kosuke Kashiwabara, Minehiko Inomata, Motoko Tachihara, Kazuhisa Tanaka, Kenji Hayashihara, Nobuyuki Koyama, Kaoru Matsui, Koichi Minato, Daisuke Jingu, Hiroyuki Sakashita, Satoshi Hara, Tomoyuki Naito, Asuka Okada, Masayuki Tanahashi, Yuki Sato, Koichiro Asano, Takayuki Takeda, Kensuke Nakazawa, Toshiyuki Harada, Kazuhiko Shibata, Tatsuo Kato, Etsuo Miyaoka, Ichiro Yoshino, Akihiko Gemma, Tetsuya Mitsudomi

Open source

DOI: 10.1016/j.jtocrr.2022.100404
Published: 2022-11
Container: JTO Clinical and Research Reports
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.jtocrr.2022.100404,
  title = {Real-World Data Analysis of Pembrolizumab Monotherapy for NSCLC Using Japanese Postmarketing All-Case Surveillance Data},
  author = {Hideki Terai and Kenzo Soejima and Asanao Shimokawa and Hidehito Horinouchi and Junichi Shimizu and Tetsunari Hase and Ryota Kanemaru and Kana Watanabe and Kiichiro Ninomiya and Naoko Aragane and Noriko Yanagitani and Yoshihiko Sakata and Masahiro Seike and Daichi Fujimoto and Masashi Kasajima and Akihito Kubo and Sojiro Kusumoto and Yoshitaka Oyamada and Keiichi Fujiwara and Masahide Mori and Midori Hashimoto and Masato Shingyoji and Masahiro Kodani and Jin Sakamoto and Toshihiko Agatsuma and Kosuke Kashiwabara and Minehiko Inomata and Motoko Tachihara and Kazuhisa Tanaka and Kenji Hayashihara and Nobuyuki Koyama and Kaoru Matsui and Koichi Minato and Daisuke Jingu and Hiroyuki Sakashita and Satoshi Hara and Tomoyuki Naito and Asuka Okada and Masayuki Tanahashi and Yuki Sato and Koichiro Asano and Takayuki Takeda and Kensuke Nakazawa and Toshiyuki Harada and Kazuhiko Shibata and Tatsuo Kato and Etsuo Miyaoka and Ichiro Yoshino and Akihiko Gemma and Tetsuya Mitsudomi},
  year = {2022},
  journal = {JTO Clinical and Research Reports},
  doi = {10.1016/j.jtocrr.2022.100404},
  url = {https://doi.org/10.1016/j.jtocrr.2022.100404}
}

RIS

TY  - JOUR
TI  - Real-World Data Analysis of Pembrolizumab Monotherapy for NSCLC Using Japanese Postmarketing All-Case Surveillance Data
AU  - Hideki Terai
AU  - Kenzo Soejima
AU  - Asanao Shimokawa
AU  - Hidehito Horinouchi
AU  - Junichi Shimizu
AU  - Tetsunari Hase
AU  - Ryota Kanemaru
AU  - Kana Watanabe
AU  - Kiichiro Ninomiya
AU  - Naoko Aragane
AU  - Noriko Yanagitani
AU  - Yoshihiko Sakata
AU  - Masahiro Seike
AU  - Daichi Fujimoto
AU  - Masashi Kasajima
AU  - Akihito Kubo
AU  - Sojiro Kusumoto
AU  - Yoshitaka Oyamada
AU  - Keiichi Fujiwara
AU  - Masahide Mori
AU  - Midori Hashimoto
AU  - Masato Shingyoji
AU  - Masahiro Kodani
AU  - Jin Sakamoto
AU  - Toshihiko Agatsuma
AU  - Kosuke Kashiwabara
AU  - Minehiko Inomata
AU  - Motoko Tachihara
AU  - Kazuhisa Tanaka
AU  - Kenji Hayashihara
AU  - Nobuyuki Koyama
AU  - Kaoru Matsui
AU  - Koichi Minato
AU  - Daisuke Jingu
AU  - Hiroyuki Sakashita
AU  - Satoshi Hara
AU  - Tomoyuki Naito
AU  - Asuka Okada
AU  - Masayuki Tanahashi
AU  - Yuki Sato
AU  - Koichiro Asano
AU  - Takayuki Takeda
AU  - Kensuke Nakazawa
AU  - Toshiyuki Harada
AU  - Kazuhiko Shibata
AU  - Tatsuo Kato
AU  - Etsuo Miyaoka
AU  - Ichiro Yoshino
AU  - Akihiko Gemma
AU  - Tetsuya Mitsudomi
PY  - 2022
JO  - JTO Clinical and Research Reports
DO  - 10.1016/j.jtocrr.2022.100404
UR  - https://doi.org/10.1016/j.jtocrr.2022.100404
ER  -

APA

Terai, H., Soejima, K., Shimokawa, A., Horinouchi, H., Shimizu, J., Hase, T., Kanemaru, R., Watanabe, K., Ninomiya, K., Aragane, N., Yanagitani, N., Sakata, Y., Seike, M., Fujimoto, D., Kasajima, M., Kubo, A., Kusumoto, S., Oyamada, Y., Fujiwara, K., Mori, M., Hashimoto, M., Shingyoji, M., Kodani, M., Sakamoto, J., Agatsuma, T., Kashiwabara, K., Inomata, M., Tachihara, M., Tanaka, K., Hayashihara, K., Koyama, N., Matsui, K., Minato, K., Jingu, D., Sakashita, H., Hara, S., Naito, T., Okada, A., Tanahashi, M., Sato, Y., Asano, K., Takeda, T., Nakazawa, K., Harada, T., Shibata, K., Kato, T., Miyaoka, E., Yoshino, I., Gemma, A., & Mitsudomi, T. (2022). Real-World Data Analysis of Pembrolizumab Monotherapy for NSCLC Using Japanese Postmarketing All-Case Surveillance Data. JTO Clinical and Research Reports. https://doi.org/10.1016/j.jtocrr.2022.100404

Source records

crossref · retrieved 2026-09-26T23:31:41.976Z